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Abstract
Aim: A prospective open-label study comparing the efficacy and safety of methotrexate (MTX) and chloro-
quine (CQ) in articular and cutaneous manifestations of systemic lupus erythematosus (SLE).
Methods: Consecutive SLE patients were randomly assigned to either 10 mg MTX weekly or 150 mg CQ daily
during 24 weeks. Outcome measures were: numbers of swollen and tender joints, duration of morning stiff-
ness, visual analog scale (VAS) for articular pain, physician global assessment index, patient global assessment
index, SLE Disease Activity Index (SLEDAI), disappearance of skin rash and erythrocyte sedimentation rate
(ESR).
Results: Forty-one patients consented to participate, 15 were allocated in the MTX group and 26 in the CQ
group. Two patients on MTX dropped out due to side-effects and two in the CQ group, one due to side-effects
and one due to inefficacy. Baseline demographic, clinical and laboratory parameters of the two groups were
nearly identical. In both groups the clinical and laboratory parameters improved significantly over 24 weeks,
except the ESR in the MTX group. The results of the outcome measures at the end of the trial did not differ
significantly between the two groups, except morning stiffness (P < 0.05 in favor of the MTX group) and ESR
(P < 0.01 in favor of the CQ group). Rise of serum alanine aminotransferase was observed in two cases in the
MTX group and in none in the CQ group.
Conclusion: Low-dose MTX appears to be as effective as CQ in patients with articular and cutaneous mani-
festations of SLE, having an acceptable toxicity profile. Results of this prospective study need to be confirmed
in a larger study.
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INTRODUCTION
Arthralgia and arthritis occur in approximately 90%
and skin and mucous membranes are involved in
80% of cases of systemic lupus erythematosus (SLE).1
Conventionally, antimalarials are used to control these
articular and mucocutaneous manifestations in non-
organ threatening SLE.2 In a recent review of 95 arti-
cles on antimalarial treatment in SLE, high levels of
evidence were found that both hydroxychloroquine
(HCQ) and chloroquine (CQ) prevent lupus flares
and increase long-term survival of patients with SLE;
moderate evidence was found of protection against
irreversible organ damage, thrombosis and bone mass
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loss.3 Toxicity related to antimalarials is infrequent,
mild and usually reversible,3 with HCQ having a safer
profile than CQ, although comparative data come
only from one observational study.4
In a retrospective study assessing the reasons for dis-
continuation of antimalarial drugs in SLE patients,
42% discontinued HCQ due to disease remission, 8%
due to inefficacy and 29% stopped because of adverse
effects, particularly severe anorexia, nausea, headache
dizziness, deafness, visual disturbance and myopathy.5
In a substantial proportion of cases, antimalarials
induce and maintain only partial remission, necessitat-
ing addition of low to high doses of corticosteroids
and sometimes cytotoxic drugs like azathioprine or
cyclophosphamide, and antimalarials are especially
inadequate in managing severe lupus, especially lupus
nephritis.6
The high efficacy/toxicity trade-off and high long-
term drug survival rates of methotrexate (MTX) have
been documented in rheumatoid arthritis patients in
several clinical trails7,8 and meta-analyses.9 Despite
existence of some evidence as early as 1965,10 the
interest in the effects of MTX in SLE has grown only
in recent years. In 1965, Miescher and Riethmu¨ller10
used MTX at a dose of 50 mg/week intravenously in
10 SLE patients with arthralgia, skin rash and vascular
purpura. They noted a rapid response: the manifesta-
tions of SLE diminished within 1 or 2 weeks. Subse-
quently, MTX was proven to be effective in controlling
articular and cutaneous manifestations of SLE in sev-
eral clinical trials.11–21 A few of these trials were retro-
spective.14,22,23 Other trials were uncontrolled and
included either steroid-resistant patients13,15,20,21 or
patients dependent on high doses of steroids.14,16–18
To our knowledge only two prospective randomized
placebo-controlled trials on the effect of MTX in SLE
have been published. The first by Carneiro and Sato24
reported the efficacy of 15–20 mg MTX in 41 patients
controlling cutaneous and articular activity of SLE and
corticosteroid dose reduction. Side-effects were fre-
quent (gastrointestinal complaints and hepatic enzyme
elevations) but only two out of 18 receiving MTX had
to stop due to toxicity. A recent trial25 showed in a
12-month study a steroid-sparing effect of MTX 7.5
increasing to 20 mg per week plus folic acid in 86 ran-
domized patients with moderately active rather than
severe lupus. To our knowledge the efficacy of MTX in
non-severe SLE has been reported in only two double-
blind placebo-controlled trials.21,22 Considering the
lack of tolerability or efficacy of antimalarials in sub-
sets of patients and the long-term efficacy of MTX in
steroid-resistant SLE and its relative safety, despite
sometimes considerable side effects,24,25 it has become
imperative to investigate its status as an alternative for
antimalarials in non-organ-threatening articular and
cutaneous SLE.
The present study was undertaken to compare the
efficacy and toxicity of MTX with those of CQ in
muco-cutaneous and articular SLE. The rationale is
that in some cases antimalarials have insufficient effect
and side-effects and a second affordable effective drug
is necessary in developing countries such as Bangla-
desh. In this study CQ 150 mg base tablet daily was
chosen as it is the only antimalarial drug available for
SLE in Bangladesh due to its low price.
We chose to keep a fixed weekly dose of 10 mg
MTX for the whole duration of the study, in order to
assess the outcome at a fixed and low dose. The
weight of most of the patients was in the range of 35–
45 kg, so the dosage per kg is comparable with that of
higher dosages as used in Western countries, where
people tend to have higher weight. We decided to
study the efficacy at a stable and low MTX dose as
many of the patients in daily Bangladeshi practice are
using medical treatment without regular clinical fol-
low-ups, due to often long distances to the hospitals
and lack of funds to do blood tests. This means that
changing dosages, in these often illiterate patients,
would be difficult to control. Obviously, during our
study all participating patients came for follow-up and
laboratory tests at the allocated times.
MATERIALS AND METHODS
This prospective open-label randomized clinical trial
was conducted at the lupus clinic of a tertiary care
center in Dhaka, the capital of Bangladesh. The study
period was June 2001 to November 2002 and
included 6-month follow-up. Patients fulfilling Ameri-
can College of Rheumatology (ACR) criteria of SLE
and suffering from arthralgia, or arthritis and active
skin lesions, were selected for this study. A total of five
patients refused to participate after explanation. Exclu-
sion criteria were: involvement of any other systems,
pregnancy, lactation, any form of eye problems, his-
tory of taking antimalarials within the last 4 months
or corticosteroids equivalent to > 20 mg of predniso-
lone per day, raised serum alanine aminotransferase
(ALT), and raised serum creatinine.
All patients gave verbal consent. No written consent
was attempted because participants were mostly illit-
erate. After obtaining informed verbal consent, the
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subjects were evaluated clinically and the following
laboratory tests were done: routine urinalysis, com-
plete blood counts (CBC), erythrocyte sedimentation
rate (ESR), antinuclear antibodies (ANA), anti-double-
stranded DNA (anti-dsDNA), serum ALT and creati-
nine. Serology-like anti-Sjo¨gren syndrome A and B
and antiphospholipid antibodies were not done due
to financial constraints.
The patients were randomly allocated to either MTX
or CQ groups. Randomization was performed follow-
ing a random number table without considering their
presentation. We followed the vertical series of odd
and even numbers.
Methotrexate was given at a dose of 10 mg/week
and CQ 150 mg per day to the respective groups
throughout the study period of 24 weeks. The patients
were allowed to continue corticosteroids in a fixed
dose that they were taking for at least 2 months before
the start of the study and at doses not exceeding
10 mg/day. Increasing the dose was not permitted,
also not in any other route like intramuscular, intrave-
nous or intra-articular.
Measures
As this study was restricted to cases with skin and
joint lesions, we used the ACR core set of outcome
measures which are often used in studies in (rheuma-
toid) arthritis patients.26 Outcome measures were:
number of swollen and tender joints; duration of
morning stiffness; visual analog scale (VAS) for articu-
lar pain, physician’s global assessment index, patient’s
global assessment index and ESR. As a multi-item dis-
ease activity measure we calculated the SLE Disease
Activity Index (SLEDAI).27
For the skin we used the disappearances of skin rash
as an outcome measure. Skin lesions of any type such
as subacute cutaneous lupus erythematosus (SCLE),
chronic discoid lupus erythematosus (CDLE), and but-
terfly rash were scored as present or absent.
Side-effects were recorded at each visit. CBC, serum
ALT and creatinine were measured every 2 weeks dur-
ing the first month and monthly thereafter as follow-
up tests. Ophthalmic evaluation was performed at the
end of 6 months.
Statistics
Data were entered into SPSS 10.1 (SPSS Inc., Chicago,
IL, US). In case of continuous variables, significance of
difference between groups was assessed by Student’s
t-test in cases of normally distributed, and Mann–
Whitney U-test in non-normally distributed observa-
tions. Within-group differences between pre- and post-
treatment measures were assessed by Wilcoxon signed
rank test. The differences between pre- and post-treat-
ment values of discrete variables were assessed by Fish-
er’s exact test. The final analysis was not done with
intention to treat, and only done in the 37 out of 41
who completed the 24 weeks period.
Ethics
The study was approved by the Ethics Committee of
the Bangabandhu Sheikh Mujib Medical University
Shahbagh, Dhaka, Bangladesh. The study was per-
formed following the Declaration of Helsinki princi-
ples and informed (oral) consent was obtained from
all participants before enrolment. As most patients
were illiterate, we explained the method orally to the
patients and their families and gave extensive possibil-
ity for them to ask any questions.
RESULTS
Forty-one subjects consented to participate in the
trial. According to the random order 15 were allo-
cated to the MTX and 26 to the CQ group. Two
patients in the MTX group were excluded from ther-
apy, one due to central nervous system involvement,
manifested by convulsions, and another due to hepa-
titis. Two patients in the CQ group discontinued
therapy, one due to lack of efficacy and one due to
psychosis (the psychosis improved after discontinua-
tion of CQ).
Out of 37 completers, 36 were female. Baseline
demographic, clinical and laboratory parameters were
nearly identical in the two groups (Table 1). All
patients were positive for ANA and at the start of the
study all had anti-dsDNA antibodies. After 24 weeks
in the CQ group in 8/24 cases dsDNA was still posi-
tive and in the MTX group 4/15 still had increased
dsDNA. Two patients in the MTX group and four in
the CQ group were on a stable dosage of predniso-
lone, with a maximum of 10 mg. As our patients were
poor, they could not afford using sunscreen and/or
topical steroids.
At baseline the groups did not differ regarding age,
sex, illness duration, duration of morning stiffness,
joint swelling and pain and VAS pain, patient and
physician global assessment (Table 1). The rather high
joint tenderness and duration of morning stiffness in
both groups may be ascribed to the humid climate, or
to sometimes exaggerated estimation by these illiterate
patients.
M. N. Islam et al.
64 International Journal of Rheumatic Diseases 2012; 15: 62–68
In the CQ group, all outcome measures improved
significantly during the study period. In the MTX
group, over 24 weeks, SLEDAI and all clinical and lab-
oratory parameters except ESR improved significantly
compared to baseline values (Table 2).
The findings in the outcome measures at the end
of the trial did not differ significantly between
groups, except morning stiffness (P < 0.05 in favor of
MTX group) and ESR (P < 0.01 in favor of CQ
group) (Table 2). Improvement of skin rash (near
disappearance) was significant in both groups but
differences between groups were non-significant
(Table 3).
Side effects
Anorexia and nausea were common in both groups.
Seven patients in the MTX group and four in the CQ
group noticed anorexia and nausea. In most cases
anorexia and nausea were mild and all subjects were
able to continue the drugs and complete the trial. Rise
of serum ALT was observed in two cases in the MTX
group. Viral markers were found negative in these
Table 2 Changes in the outcome measures in methotrexate (n = 13) and chloroquine (n = 24) groups
Variables Methotrexate group Chloroquine group Inter-group
P
0 week
(mean  SD)
24 weeks
(mean  SD)
P* 0 week
(mean  SD)
24 weeks
(mean  SD)
P*
Number of swollen joint 7.77  9.68 0.77  1.74 < 0.05 2.7  4.6 1.1  2.9 < 0.05 NS
Joint swelling index 11.7  19.4 1.4  3.1 < 0.05 3.4  5.7 1.4  3.4 < 0.05 NS
Number of tender joint 20.1  10.0 3.3  5.3 < 0.01 15.2  11.2 4.1  6.7 < 0.001 NS
Joint tenderness index 35.7  21.7 4.5  9.1 < 0.01 23.0  17.4 4.8  9.8 < 0.001 NS
Morning stiffness (minute) 45.0  27.0 7.7  14.8 < 0.01 29.4  29.0 10.4  22.6 < 0.01 NS
VAS for pain 5.4  2.3 1.4  2.1 < 0.01 4.5  2.6 1.5  2.2 < 0.001 NS
Physician global
assessment index
3.4  0.7 1.5  1.1 < 0.01 3.3  1.0 1.8  1.1 < 0.001 NS
Patient assessment index 3.5  0.7 1.6  1.2 < 0.01 3.3  0.8 1.9  1.1 < 0.01 NS
ESR (mm at 1st h) 73.5  38.7 57.3  29.1 NS 56.9  30.4 35.0  21.6 < 0.001 < 0.01
SLEDAI 12.5  1.2 2.8  2.4 < 0.01 13.3  0.5 2.5  2.4 < 0.001 NS
*Wilcoxon signed-rank test. ESR, erythrocyte sedimentation rate; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; VAS, visual
analog scale.
Table 1 Baseline characteristics of methotrexate and chloroquine groups
Characteristics Methotrexate (n = 13)
(mean  SD)
Chloroquine (n = 24)
(mean  SD)
P-value
Age (years) 24.0  4.5 24.9  7.0 0.299
Sex (female/male) 13/0 23/1
Duration of illness (months) 15.4  12.1 12.2  9.5 0.216
Number of swollen joint 7.8  9.7 2.7  4.6 0.499
Joint swelling index 11.7  19.4 3.4  5.7 0.475
Number of tender joint 20.1  10.0 15.2  11.2 0.311
Joint tenderness index 35.7  21.7 23.0  17.4 0.233
Morning stiffness (min) 45.0  27.0 29.4  29.0 0.386
VAS for pain 5.4  2.3 4.5  2.6 0.251
Physician’s global assessment index 3.4  0.7 3.3  1.0 0.221
Patient’s global assessment index 3.5  0.7 3.3  0.8 0.226
Skin rash 6 19 0.499
ESR (mm/1st h) 73.5  38.7 56.9  30.4 0.455
ALT (U/L) 35.0  14.0 28.2  10.8 0.212
Platelet count (per mm3) 240,308  124,751 288,542  77,871 0.412
Total white blood cell count (cm3) 7,415  2,105 7,242  2,443 0.122
Hemoglobin (g/dL) 10.3  1.6 10.8  1.5 0.102
ALT, alanine aminotransferase; ESR, erythrocyte sedimentation rate; VAS, visual analog scale.
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cases and the liver functions became normal after dis-
continuation of MTX. The number of adverse events
was significantly higher in the MTX group compared
to the CQ group (Table 4). The ophthalmic evaluation
at the end of 6 months did not reveal any abnormali-
ties in either group of patients. No flares of SLE or
end organ damage were observed during the study.
DISCUSSION
The role of antimalarials in the treatment of cutaneous
and articular manifestations of SLE has been well
established.3,28–31 In some retrospective and uncon-
trolled studies, MTX has been reported to be effective
in controlling steroid-dependent or steroid-resistant
articular and cutaneous manifestations of SLE.10–21 A
few of these trials were retrospective.14,22,23 Other
trials were uncontrolled and included either steroid-
resistant patients13,15,20,21 or patients dependent on
high doses of steroid.14,16–18
Only two prospective randomized placebo-con-
trolled trials on the efficacy of MTX in SLE have been
published, both showing good effect of MTX on
controlling cutaneous and articular activity of SLE
and corticosteroid dose reduction despite frequent
side-effects (gastrointestinal complaints and hepatic
enzyme elevations). In both studies higher MTX dos-
ages were used than in ours. A recent trial25 was done
in a more severe patient group and half the patients
had renal and two-thirds cardiovascular, hematologic
and other organ involvements. In either arms of the
study two-thirds or virtually all (placebo arm) of the
patients received HCQ so the results of this study can-
not be compared with ours.
None of the studies addressed the issue of safety
and efficacy of MTX compared to those of antimalari-
als. These studies opened our eyes to the use of MTX
in articular and cutaneous SLE, but they did not
answer the question if MTX could be used as an alter-
native for antimalarials.
Our prospective, controlled study was the first one
designed to compare the efficacy and safety of MTX
with CQ in patients with articular and cutaneous
lupus not resistant to or dependent on high-dose cor-
ticosteroids. As with the previous studies, we demon-
strated the efficacy of MTX in controlling articular and
mucocutaneous manifestations of SLE. There was a
significant improvement in outcome measures in both
MTX and CQ groups and the two groups did not sig-
nificantly differ at the end of the 24-week trial period
in most outcome measures. This indicates that MTX is
as effective as CQ in articular and mucocutaneous
SLE. However, two observations in our limited trial
need re-investigation. The fall in ESR was not signifi-
cant in the MTX group. This may reflect the well-
known fact that ESR does not correlate with disease
activity in SLE and is mainly an indication of, for
example, infection. Alternatively, antimalarials might
be more effective in controlling some aspects of SLE
than MTX. The adverse reactions, although not severe
enough to warrant withdrawal of the drug, were more
frequent in the MTX group. In rheumatoid arthritis,
MTX is more potent than antimalarials, but in many
cases higher dosages of MTX are needed to get an opti-
mal effect. If we had used a higher dose of MTX, the
result might have been that MTX would appear to be
more effective than CQ. On the other hand, the
patients had a very low weight and the dosage per kg
used in our study is comparable with about 20 mg/
week in a Western population. In any case, further
studies are needed.
We feel that there is a role for MTX in the treatment
of patients with articular and mucocutaneous SLE. In
daily practice a failure of antimalarial drugs often
results in long-term treatment with higher doses of cor-
ticosteroids. Our findings and those of others25 indi-
cate that MTX can be used as a steroid-sparing agent.
Cyclophosphamide and azathioprine are also effective
and have steroid-sparing potential, but there is concern
about the risks of carcinogenicity or irreversible steril-
ity.32,33 To date no evidence of carcinogenicity has
Table 3 Number of subjects with skin rash before and after
treatment
Group Total At 0
week
At 24
weeks
P-value Inter-group
P
Methotrexate 13 06 0 < 0.001 NS
Chloroquine 24 19 03 < 0.001
NS, not significant.
Table 4 Adverse effects of methotrexate and chloroquine
after 24 weeks
Adverse effects Methotrexate
(n = 13)
(%)
Chloroquine
(n = 24)
(%)
P*
Anorexia and
nausea
7 (53.8) 4 (16.7) < 0.01
Raised ALT 2 (15.4) 0
Total 9 (69.2) 4 (16.7)
*Fisher’s exact test. ALT, alanine aminotransferase.
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been reported with MTX. So MTX may be preferable to
these agents.
We permitted enrolment of patients on stable dos-
age of maximum 10 mg prednisolone during the last
2 months before enrolment and no addition or
change of dose during the trial period was allowed.
Only two patients in the MTX group and four in CQ
group were using corticosteroids, so no subgroup anal-
ysis was done.
Our study had several limitations and flaws that
need to be specifically addressed in designing future
studies on efficacy of MTX in SLE. The first limitation
is that the study was designed as an equivalence trial,
trying to demonstrate that MTX is equivalent to CQ.
Although generally no differences were found between
the efficacy of MTX and CQ, the small sample size in
this study may have masked some true differences
between the groups. To confidently conclude that
there is absolutely no difference between the two treat-
ments, one would need a very large sample size in
order to achieve enough power to identify even small
differences on all outcome measures. Therefore, the
conclusion that MTX is equivalent to CQ needs to be
interpreted with some caution. Although we realize
that the sample size in this study was quite small, as it
is in most studies on this issue, we had to make do
with the available number of SLE cases fulfilling the
criteria. SLE is a rare disease34 and studies with larger
samples need multi-center collaboration.
Another flaw of our study is that there was no
blinding to treatment and this may have biased the
outcomes. Owing to lack of financial and logistic sup-
port, we could not make a double-blind design. But
we do not feel that this has influenced the results, as
the majority of the patients were illiterate, so in that
way they were more or less blinded. Moreover, this
study was done without any funding from industry or
government.
We were compelled to use in CQ instead of HCQ,
the antimalarial more commonly used in SLE. HCQ is
more expensive and not available in Bangladesh and
many parts of the world. Moreover, it has been sug-
gested that CQ might be more effective although more
toxic than HCQ.35 Both HCQ and CQ have compara-
ble immunomodulatory and anti-inflammatory effects
and are effective in SLE.3,36 Doses used for both MTX
and CQ may appear subtherapeutic. Although we con-
sidered applying higher or flexible dosages like the
treatment schemes applied in rheumatoid arthritis
used in Western countries, we decided to choose in
this study for low and fixed dosages in these patients
with a weight of generally 35–45 kg. Additionally, we
did not give folic acid as a supplement, which consid-
ering the current literature in RA would have been
preferable. Despite this, we observed few side-effects
in the MTX-treated patients.
The assessment of the skin lesions was rather crude –
either presence or absence of skin lesions. We did not
allow changes in corticosteroid dosages, so possible
changes can be ascribed only to MTX or CQ treatments.
A follow-up period of 6 months, as it was applied
in most previous studies with MTX in SLE, does not
establish sustained efficacy, so in the future longer
follow-up is needed.
CONCLUSIONS
As a result of our study we conclude that both drugs
are useful in SLE patients with skin and articular com-
plaints and as both drugs are cheap and affordable in
our country, we advise its use for the benefit of our
patients.
Long-term multi-center double-blind collaborative
studies, including large samples, will further clarify the
relative safety, efficacy and cost-effectiveness of MTX in
the treatment of articular and cutaneous lupus as an
alternative to the antimalarials.
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